Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope.
Peter J ChoiThomas I H ParkElizabeth CooperMike DragunowWilliam Alexander DennyJiney JosePublished in: Bioconjugate chemistry (2020)
This review covers the application of heptamethine cyanine dye (HMCD) mediated drug delivery. A relatively small number of HMCDs possess tumor targeting abilities, and this has spurred interest from research groups to explore them as drug delivery systems. Their tumor selectivity is primarily attributed to their uptake by certain isoforms of organic anion transporting polypeptides (OATPs) which are overexpressed in cancer tissues, although there are other possible mechanisms for the observed selectivity still under investigation. This specificity is confirmed using various cancer cell lines and is accompanied by moderate cytotoxicity. Their retention in tumor tissue is facilitated by the formation of albumin adducts as revealed by published mechanistic studies. HMCDs are also organelle selective dyes with specificity toward mitochondria and lysosomes, and with absorption and emission in the near-infrared region. This makes them valuable tools for biomedical imaging, especially in the field of fluorescence-guided tumor surgery. Furthermore, conjugating antitumor agents to HMCDs is providing novel drugs that await clinical testing. HMCD development as theranostic agents with dual tumor targeting and treatment capability signals a new approach to overcome drug resistance (mediated through evasion of efflux pumps) and systemic toxicity, the two parameters which have long plagued drug discovery.
Keyphrases
- drug delivery
- drug discovery
- cancer therapy
- minimally invasive
- photodynamic therapy
- papillary thyroid
- oxidative stress
- coronary artery disease
- squamous cell carcinoma
- structural basis
- highly efficient
- randomized controlled trial
- young adults
- coronary artery bypass
- ionic liquid
- single molecule
- atrial fibrillation
- reactive oxygen species
- solid state